Emerging drugs for endometriosis
The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Endometriosis is a benign, common gynecological disorder affecting mostly women of reproductive age. It is associated with dysmenorrhea, pelvic pain, and subfertility. The current non-surgical medical treatment is not satisfactory and there is a pressing need for novel therapeutics with better efficacy, tolerability and safety profiles. OBJECTIVE: To investigate the development of new therapies for endometriosis. METHODS: The PubMed database has been extensively searched for all compounds tested preclinically and clinically. RESULTS/CONCLUSION: Besides the three main classes of drugs, i.e., GnRH agonists, progestins, and androgenic agents, there are several classes of compounds that have been tested preclinically and clinically. Surprisingly, a considerable proportion of officially registered Phase II/III clinical trials are listed as completed yet no information on their outcomes is available. Three completed and published Phase II trials found the tested compound disappointing. Another two Phase II clinical trials have been suspended. This apparent gap between the generally promising preclinical findings and the clinical trial outcomes reflects our current woefully inadequate understanding of the mechanisms underlying endometriosis-associated pain and subferitility and recurrence of endometriosis; questions the adequacy and value of animal models of endometriosis that are still in use; highlights the difficulty in developing new therapeutics for endometriosis; and calls for more research in the mechanisms underlying endometriosis-associated pain and subferitility and recurrence of endometriosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Roles of PPARs in health and disease
Kersten, S., Desvergne, B., & Wahli, W. (2000) · Nature · doi:10.1038/35013000 · Cited by 1,956 · cited 2×
“For the PPAR- γ /RXR heterodimers, the binding of the ligand of either receptor can activate the complex, yet binding of both ligands simultaneously is more potent [177,178] .”
BackgroundThe PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816 · cited 6×
“(PPAR-g ) agonists and retinoid X receptor (RXR) ligands PPAR- γ is activated by fatty acid derivatives, thiazolidinediones (TZDs), and by certain NSAIDs [162,163] .”
BackgroundInfluentialEskenazi, B., & Warner, M. L. (1997) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/s0889-8545(05)70302-8 · Cited by 1,617
ESHRE guideline for the diagnosis and treatment of endometriosis
Kennedy, S., Bergqvist, A., Chapron, C., D’Hooghe, T., Dunselman, G., Greb, R., Hummelshoj, L., Prentice, A., & Saridogan, E. (2005) · Human Reproduction · doi:10.1093/humrep/dei135 · Cited by 1,584 · cited 4×
“All hormonal treatments are equally effective in relieving pains [13] ; however, the relief appears to be relatively shortterm [14] .”
BackgroundInfluentialAn integrative genomics approach to infer causal associations between gene expression and disease
Schadt, E. E., Lamb, J., Yang, X., Zhu, J., Edwards, S., GuhaThakurta, D., Sieberts, S. K., Monks, S., Reitman, M., Zhang, C., et al. (2005) · Nature Genetics · doi:10.1038/ng1589 · Cited by 1,043 · cited 1×
“Though piecemeal approaches may be necessary to dissect individual components of the system, developing a novel drug with the desired efficacy, tolerability and safety requires a system-wide approach [290,291] .”
BackgroundLaparoscopic Surgery in Infertile Women with Minimal or Mild Endometriosis
Marcoux, S., Maheux, R., & Bérubé, S. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707243370401 · Cited by 948
Nuclear factor-?B: its role in health and disease
Kumar, A., Takada, Y., Boriek, A., & Aggarwal, B. (2004) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0555-y · Cited by 933
Kao, L. C., Germeyer, A., Tulac, S., Lobo, S., Yang, J. P., Taylor, R. N., Osteen, K., Lessey, B. A., & Giudice, L. C. (2003) · Endocrinology · doi:10.1210/en.2003-0043 · Cited by 696 · cited 2×
“8 HDACIs Numerous studies have shown that many genes in endometriotic lesions are dysregulated [87,234,236] .”
BackgroundAromatase expression in endometriosis.
Noble, L. S., Simpson, E. R., Johns, A., & Bulun, S. E. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550748 · Cited by 566 · cited 2×
“For GnRH-a treatment, two sources of extraovarian estrogen production may render the treatment ineffective [20] : increased local production of estrogen within the ectopic implants due to aberrant expression of aromatase and 17 β HSD2 [21,22] , and estradiol produced in peripheral tissues.”
BackgroundVercellini, P., Fedele, L., Aimi, G., Pietropaolo, G., Consonni, D., & Crosignani, P. G. (2007) · Human Reproduction · doi:10.1093/humrep/del339 · Cited by 547 · cited 1×
“In addition, the association between endometriosis stage and severity of pelvic symptoms is marginal and inconsistent [285,286] .”
BackgroundBulun, S. E., Lin, Z., Imir, G., Amin, S., Demura, M., Yilmaz, B., Martin, R., Utsunomiya, H., Thung, S., Gurates, B., et al. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.3.6 · Cited by 531 · cited 4×
“In addition, they have many undesirable, and sometimes severe, side effects [15-17] .”
BackgroundInfluentialOxidative stress and peritoneal endometriosis
Van Langendonckt, A., Casanas-Roux, F., & Donnez, J. (2002) · Fertility and Sterility · doi:10.1016/s0015-0282(02)02959-x · Cited by 391
dell'Endometriosi, G. I. P. L. S. (1999) · Human Reproduction · doi:10.1093/humrep/14.5.1332 · Cited by 370
Promoter Methylation Regulates Estrogen Receptor 2 in Human Endometrium and Endometriosis1
Xue, Q., Lin, Z., Cheng, Y.-H., Huang, C.-C., Marsh, E., Yin, P., Milad, M. P., Confino, E., Reierstad, S., Innes, J., et al. (2007) · Biology of Reproduction · doi:10.1095/biolreprod.107.061804 · Cited by 346 · cited 2×
“They also found that ERβ promoter also is hypomethylated, which may explain ERβ overexpression and increased ERβ /ERα expression ratio observed in ectopic implants [146] .”
BackgroundOlive, D. L., & Pritts, E. A. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107263450407 · Cited by 340
Relationship between endometriotic foci and nerves in rectovaginal endometriotic nodules
Anaf, V. (2000) · Human Reproduction · doi:10.1093/humrep/15.8.1744 · Cited by 333 · cited 1×
“Anaf and colleagues found a close histological relationship between nerves and endometriotic foci, and between nerves and the fibrotic component of the nodule, suggesting that such topographical relationships might explain the strong association between the lesion and pain [60] .”
BackgroundPromoter Hypermethylation of Progesterone Receptor Isoform B (PR-B) in Endometriosis
Wu, Y., Strawn, E., Basir, Z., Halverson, G., & Guo, S.-W. (2006) · Epigenetics · doi:10.4161/epi.1.2.2766 · Cited by 321
Self-citationAnaf, V., Simon, P., El Nakadi, I., Fayt, I., Simonart, T., Buxant, F., & Noel, J.-C. (2002) · Human Reproduction · doi:10.1093/humrep/17.7.1895 · Cited by 317 · cited 1×
“They also found higher NGF expression in deep adenomyotic nodules than in peritoneal and ovarian endometriosis, indicating a role of NGF in endometriotic pain and hyperalgesia in deep adenomyotic nodules [61] .”
BackgroundThe role of cytokines in endometriosis
Wu, M., & Ho, H. (2003) · American Journal of Reproductive Immunology · doi:10.1034/j.1600-0897.2003.01207.x · Cited by 317 · cited 2×
“These cytokines in turn induce other pro-inflammatory cytokines and chemokines, such as IL-8, CCL2 (also known as monocyte chemotactic protein or MCP1), and CCL5 (also known as RANTES), possibly through NFκ B activation [96,97] .”
BackgroundChwalisz, K., Perez, M. C., DeManno, D., Winkel, C., Schubert, G., & Elger, W. (2005) · Endocrine Reviews · doi:10.1210/er.2005-0001 · Cited by 310
Zeitoun, K., Takayama, K., Sasano, H., Suzuki, T., Moghrabi, N., Andersson, S., Johns, A., Meng, L., Putman, M., Carr, B., et al. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.12.5301 · Cited by 308
Leyendecker, G., Kunz, G., Wildt, L., Beil, D., & Deininger, H. (1996) · Human Reproduction · doi:10.1093/oxfordjournals.humrep.a019435 · Cited by 307 · cited 2×
“Dysperistalsis in the late follicular phase may compromise sperm transport, consequently impairing fertility [81] .”
BackgroundKitawaki, J., Noguchi, T., Amatsu, T., Maeda, K., Tsukamoto, K., Yamamoto, T., Fushiki, S., Osawa, Y., & Honjo, H. (1997) · Biology of Reproduction · doi:10.1095/biolreprod57.3.514 · Cited by 305
Prostaglandin E2 Stimulates Aromatase Expression in Endometriosis-Derived Stromal Cells
Noble, L. S. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.2.600 · Cited by 301
Wu, Y., Halverson, G., Basir, Z., Strawn, E., Yan, P., & Guo, S.-W. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2005.01.034 · Cited by 283 · cited 2×
“A recent study also reports that the aberrant HOXA10 expression in endometriosis may be due to its promoter hypermethylation [85] , suggesting that the defect is quite stable and may be resistant to drug intervention without any epigenetic reprograming.”
BackgroundSelf-citationTreatment of severe postmenopausal endometriosis with an aromatase inhibitor
Takayama, K., Zeitoun, K., Gunby, R. T., Sasano, H., Carr, B. R., & Bulun, S. E. (1998) · Fertility and Sterility · doi:10.1016/s0015-0282(98)00022-3 · Cited by 270
Aromatase: a key molecule in the pathophysiology of endometriosis and a therapeutic target
Zeitoun, K. M., & Bulun, S. E. (1999) · Fertility and Sterility · doi:10.1016/s0015-0282(99)00393-3 · Cited by 256
Tokushige, N., Markham, R., Russell, P., & Fraser, I. S. (2006) · Human Reproduction · doi:10.1093/humrep/dei368 · Cited by 236
Altered expression of HOXA10 in endometriosis: potential role in decidualization
Kim, J. J., Taylor, H. S., Lu, Z., Ladhani, O., Hastings, J. M., Jackson, K. S., Wu, Y., Guo, S. W., & Fazleabas, A. T. (2007) · MHR: Basic science of reproductive medicine · doi:10.1093/molehr/gam005 · Cited by 228 · cited 2×
“In fact, 6 months after the induction of endometriosis in baboons, HOXA10 promoter is found to be hypermethylated, concomitant with its downregulation [86] .”
BackgroundSoysal, S. (2004) · Human Reproduction · doi:10.1093/humrep/deh035 · Cited by 227 · cited 1×
“The only randomized clinical trial comparing GnRH-a and GnRH-a plus anastrozole (an AI) as a postsurgical regimen shows that, at the end of 24th month, the women receiving the latter treatment had a lower recurrence risk (43 vs 90%) than those receiving the former [115] .”
BackgroundXue, Q., Lin, Z., Yin, P., Milad, M. P., Cheng, Y.-H., Confino, E., Reierstad, S., & Bulun, S. E. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0494 · Cited by 219 · cited 1×
“Xue and co-workers found that the promoter region of steroidogenic factor-1 (SF-1) is hypomethylated [263] in endometriosis.”
BackgroundTreatment of endometriosis with the antiprogesterone mifepristone (RU486)
Michael Kettel, L., Murphy, A. A., Morales, A. J., Ulmann, A., Baulieu, E. E., & Yen, S. S. C. (1996) · Fertility and Sterility · doi:10.1016/s0015-0282(16)58022-4 · Cited by 216
Transcriptional characterizations of differences between eutopic and ectopic endometrium
Wu, Y., Kajdacsy-Balla, A., Strawn, E., Basir, Z., Halverson, G., Jailwala, P., Wang, Y., Wang, X., Ghosh, S., & Guo, S.-W. (2006) · Endocrinology · doi:10.1210/en.2005-0426 · Cited by 208 · cited 7×
“In addition, gene expression profiling studies clearly show that different subtypes of endometriosis, ovarian and peritoneal, for example, are transcriptionally different [236] , supporting the notion that there are different entities of endometriosis [289] .”
BackgroundInfluentialProgesterone Receptor Isoform A But Not B Is Expressed in Endometriosis1
Attia, G. R., Zeitoun, K., Edwards, D., Johns, A., Carr, B. R., & Bulun, S. E. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.8.6739 · Cited by 193
Wu, Y., Strawn, E., Basir, Z., Halverson, G., & Guo, S.-W. (2007) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.05.077 · Cited by 193 · cited 1×
“Further investigation found that three genes coding for enzymes involving genome methylation – DNA methyltransferase (DNMT)-1, 3A, and 3B – are all overexpressed in ectopic implants, suggesting that aberrant methylation may be widespread in endometriosis [262] .”
BackgroundSelf-citationInflammatory Status Influences Aromatase and Steroid Receptor Expression in Endometriosis
Bukulmez, O., Hardy, D. B., Carr, B. R., Word, R. A., & Mendelson, C. R. (2008) · Endocrinology · doi:10.1210/en.2007-0665 · Cited by 186 · cited 1×
“Although endometrial expression of ERβ appears to be reduced in women with endometriosis (or in animals with induced endometriosis) [141,142] , ERβ expression in ectopic endometrium and in macrophages of women with endometriosis has been documented to be increased [143-145] .”
BackgroundAromatase inhibitors: the next generation of therapeutics for endometriosis?
Attar, E., & Bulun, S. E. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.09.064 · Cited by 184
Anti-TNF- treatment for deep endometriosis-associated pain: a randomized placebo-controlled trial
Koninckx, P. R., Craessaerts, M., Timmerman, D., Cornillie, F., & Kennedy, S. (2008) · Human Reproduction · doi:10.1093/humrep/den177 · Cited by 165
Brandenberger, A. W. (1999) · Molecular Human Reproduction · doi:10.1093/molehr/5.7.651 · Cited by 165
Tokushige, N., Markham, R., Russell, P., & Fraser, I. S. (2007) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.12.078 · Cited by 151 · cited 1×
“In addition, they found increased nerve fiber density in endometrium and myometrium, and sensory C fibers and adrenergic nerve fibers in the endometrium in women with endometriosis [64] .”
BackgroundKettel, L. M., Murphy, A. A., Mortola, J. F., Liu, J. H., Ulmann, A., & Yen, S. S. C. (1991) · Fertility and Sterility · doi:10.1016/s0015-0282(16)54531-2 · Cited by 151 · cited 1×
“So far, four clinical series reports have been published (in the 1990s) by the same research group in international journals; all appeared to show encouraging results [125-128] .”
BackgroundEstrogen metabolizing enzymes in endometrium and endometriosis
Dassen, H., Punyadeera, C., Kamps, R., Delvoux, B., Van Langendonckt, A., Donnez, J., Husen, B., Thole, H., Dunselman, G., & Groothuis, P. (2007) · Human Reproduction · doi:10.1093/humrep/dem310 · Cited by 141 · cited 1×
“Now the consensus is that in endometriosis lesion, there is an increased local production of estrogen due to a suppression of types 2 and 4 17 β -hydroxysteroid dehydrogenases (17 β -HSDs), and an increased expression of aromatase and type 1 17 β -HSD [22,105] .”
BackgroundRegulation of HOXA-10 and its expression in normal and abnormal endometrium
Gui, Y., Zhang, J., Yuan, L., & Lessey, B. A. (1999) · MHR: Basic science of reproductive medicine · doi:10.1093/molehr/5.9.866 · Cited by 139 · cited 2×
“Endometrial expression of HOXA10 is reduced in women with endometriosis [83,84] .”
BackgroundSurgical management of endometriosis
Donnez, J., Pirard, C., Smets, M., Jadoul, P., & Squifflet, J. (2004) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2004.03.004 · Cited by 134
Endometriosis in pregnant and non-pregnant women at tubal sterilization
Moen, M. H., & Muus, K. M. (1991) · Human Reproduction · doi:10.1093/oxfordjournals.humrep.a137411 · Cited by 118
Attardi, B. J., Burgenson, J., Hild, S. A., Reel, J. R., & Blye, R. P. (2002) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(01)00743-2 · Cited by 118 · cited 1×
“One SPRM, CDB-2914, binds competitively to PR with high affinity and has little or no antiglucocorticoid activity [131] .”
BackgroundSystematic review of the effects of aromatase inhibitors on pain associated with endometriosis
Patwardhan, S., Nawathe, A., Yates, D., Harrison, G., & Khan, K. (2008) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2008.01740.x · Cited by 116
Giamberardino, M. A., Berkley, K. J., Affaitati, G., Lerza, R., Centurione, L., Lapenna, D., & Vecchiet, L. (2002) · Pain · doi:10.1016/s0304-3959(01)00405-5 · Cited by 114 · cited 1×
“In female rats, it is found that induced endometriosis influences pain behaviors and muscle hyperalgesia induced by a ureteral calculosis; this phenomenon, called ‘viscero-viseral’ hyperalgesia, is due to increased input from the cyst implantation sites to common spinal cord segments (T10 – L1), which facilitates the…”
BackgroundEvidence for estrogen synthesis in adenomyotic tissues
Yamamoto, T., Noguchi, T., Tamura, T., Kitawaki, J., & Okada, H. (1993) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(93)90654-2 · Cited by 111 · cited 1×
“The earliest interest in aromatase dates back in 1993, when it was found that the aromatase expression in adenomyotic tissues is high, suggesting that estrogen is synthesized in ectopic endometrial tissues of women with uterine adenomyosis [100] .”
BackgroundWinnard, K. P., Dmitrieva, N., & Berkley, K. J. (2006) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00455.2006 · Cited by 111
Estrous changes in vaginal nociception in a rat model of endometriosis
Cason, A. M., Samuelsen, C. L., & Berkley, K. J. (2003) · Hormones and Behavior · doi:10.1016/s0018-506x(03)00121-1 · Cited by 94
Tokushige, N., Markham, R., Russell, P., & Fraser, I. S. (2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.08.074 · Cited by 85 · cited 1×
“Remarkably, they found that hormonal treatment significantly reduced nerve fiber density in endometrium and myometrium in women with endometriosis [65] .”
BackgroundIzawa, M., Harada, T., Taniguchi, F., Ohama, Y., Takenaka, Y., & Terakawa, N. (2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.03.078 · Cited by 83 · cited 1×
“An epigenetic aberration at aromatase gene in endometriotic stromal cells also has been recently noted by Izawa and colleagues [264] .”
BackgroundZhang, G., Dmitrieva, N., Liu, Y., McGinty, K. A., & Berkley, K. J. (2008) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00649.2007 · Cited by 78
Ozawa, Y., Murakami, T., Tamura, M., Terada, Y., Yaegashi, N., & Okamura, K. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.01.057 · Cited by 76
Is the endometrium or oocyte/embryo affected in endometriosis?
Garcia-Velasco, J. A., & Arici, A. (1999) · Human Reproduction · doi:10.1093/humrep/14.suppl_2.77 · Cited by 68
Al-Jefout, M., Andreadis, N., Tokushige, N., Markham, R., & Fraser, I. (2007) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2007.04.032 · Cited by 68
Yao, Z., Shen, X., Capodanno, I., Donnelly, M., Fenyk-Melody, J., Hausamann, J., Nunes, C., Strauss, J., & Vakerich, K. (2005) · Journal of Investigative Surgery · doi:10.1080/08941930591004412 · Cited by 60
Two unsuccessful clinical trials on endometriosis and a few lessons learned
Guo, S.-W., & Olive, D. L. (2007) · Gynecologic and Obstetric Investigation · doi:10.1159/000098413 · Cited by 49 · cited 4×
“Although several lessons from two apparently unsuccessful clinical trials on endometriosis have been spelled out [47] , it is unclear whether these lessons have been learned.”
BackgroundInfluentialSelf-citationNew drugs in development for the treatment of endometriosis
Fedele, L., Somigliana, E., Frontino, G., Benaglia, L., & Vigano, P. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.8.1187 · Cited by 30
Long-term Risk of Cardiovascular Events With Rosiglitazone: A Meta-analysis
Singh, S., Loke, Y. K., & Furberg, C. D. (2007) · JAMA · doi:10.1001/jama.298.10.1189 · Cited by 5
Cited by
Recurrence of endometriosis and its control
Guo, S.-W. (2009) · Human Reproduction Update · doi:10.1093/humupd/dmp007 · Cited by 719
Self-citationContemporary genetic technologies and female reproduction
The Evian Annual Reproduction (EVAR) Workshop Group 2010, Fauser, B. C. J. M., Diedrich, K., Bouchard, P., Dominguez, F., Matzuk, M., Franks, S., Hamamah, S., Simon, C., Devroey, P., et al. (2011) · Human Reproduction Update · doi:10.1093/humupd/dmr033 · Cited by 349
Guo, S.-W. (2009) · Molecular Human Reproduction · doi:10.1093/molehr/gap064 · Cited by 328
“Since drugs for treatment of endometriosis tacitly demand better side-effect profiles (Guo, 2008), side effects would be a legitimate concern.”
BackgroundInfluentialSelf-citation“Waiting for Godot”: a commonsense approach to the medical treatment of endometriosis
Vercellini, P., Crosignani, P., Somigliana, E., Vigano, P., Frattaruolo, M. P., & Fedele, L. (2011) · Human Reproduction · doi:10.1093/humrep/deq302 · Cited by 180
“…on the topic (D’Hooghe, 2003; Nothnick and D’Hooghe, 2003; Fedele and Berlanda, 2004; Olive et al., 2004; Attar and Bulun, 2006; Chlouber et al., 2006; Crosignani et al., 2006a; Mihalyi et al., 2006; Hompes and Mijatovic, 2007; Fedele et al., 2008; Guo, 2008; Panay 2008; Ferrero et al., 2010a).”
BackgroundNew treatment strategies and emerging drugs in endometriosis
Streuli, I., de Ziegler, D., Borghese, B., Santulli, P., Batteux, F., & Chapron, C. (2012) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2012.668885 · Cited by 27
“As stated by Guo in his review, blocking TNF-a activity is still an insufficiently explored alternative and should be assessed in women with active peritoneal lesions [122].”
Background
Metadata
- Authors
- Guo, S.-W.
- Venue
- Expert Opinion on Emerging Drugs
- Publisher
- Informa UK Limited
- Published
- 2008-11-20
- Volume
- 13
- Issue
- 4
- Pages
- 547-571
- ISSN
- 1472-8214 (ISSN-L)
- 1744-7623
- OpenAlex
- W2163398199
- Cited by
- 24
- References
- 61
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.